Company Overview
Snapshot
Founded in January 2021 by Immanuel Lerner and Anwar Rayan, PeptiCov operates with 1–10 employees. The company was established following a $2.6 million funding round led by Chartered Group in March 2021, aimed at developing treatments for SARS-CoV-2.
Business overview
PeptiCov is a biotechnology company focused on the discovery and development of effective treatments for SARS-CoV-2. As a spin-off from PeptiCom, it leverages artificial intelligence technology to streamline peptide drug discovery. This AI-driven approach accelerates the identification of advanced peptide-based drug candidates, covering a broad range of molecular options while filtering for optimal properties like solubility and permeability. PeptiCov specifically develops these AI-designed peptides for coronavirus SARS-CoV-2 and seeks partnerships with pharmaceutical companies for further development. The company operates within the Health Tech & Life Sciences sector, with a focus on Medical Treatment & Therapeutics and Digital Healthcare.
Strategic signal
In March 2021, PeptiCov secured $2.6 million in funding from Chartered Group to establish operations and advance its mission to combat COVID-19. This investment highlights investor confidence in AI-driven drug discovery platforms for rapid response to global health crises, signaling a strategic validation of PeptiCov's approach to developing novel peptide molecules for SARS-CoV-2 treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is PeptiCov's primary focus?
- PeptiCov is focused on discovering and developing an effective treatment for SARS-CoV-2, utilizing artificial intelligence to streamline peptide drug discovery.
- When was PeptiCov founded?
- PeptiCov was founded in January 2021.
- Who are the founders of PeptiCov?
- PeptiCov was founded by Immanuel Lerner and Anwar Rayan.
- What was a significant financial event for PeptiCov?
- In March 2021, PeptiCov raised $2.6 million in funding, led by Chartered Group, to establish the company and focus on developing treatments for SARS-CoV-2.
- How does PeptiCov leverage technology in its drug discovery process?
- PeptiCov utilizes AI technology, spun off from PeptiCom, to accelerate the discovery of advanced peptide-based drug candidates by searching a vast array of solutions and filtering for suitable properties like solubility and permeability.